Drug combination | Sarcoma tumor models | Results compared to models treated with chemotherapy alone | Reference |
---|---|---|---|
Pazopanib + topotecan | OS KHOS and RMS RH30 cell lines and xenografts | ↑ Antitumor and antiangiogenic effects, ↑ Survival, ↓ Circulating endothelial cells and/or endothelial progenitor cells, ↓ MVD | [30] |
VDA (OXi4503/CA1P) + doxorubicin | EWS xenografts | ↑ Antitumor effects ↑ Necrosis ↓ Perfused vasculature | [59] |
Bevacizumab + topotecan | ASPS xenografts | ↑ Antitumor effects compared to bevacizumab monotherapy, but not topotecan alone | [60] |
Vandetanib + doxorubicin | Multiple STS cell lines and xenografts | ↑ Antitumor and antiangiogenic effects ↓ Local growth leiomyosarcoma ↓ Lung metastases in fibrosarcoma | [31] |
DC101 + doxorubicin | Multiple STS cell lines and xenografts transfected with VEGF165 | ↑ Antitumor and antiangiogenic effects ↓ Tumor growth and pulmonary metastases ↓ MVD ↑ Percentage of mature vessels ↓ Matrix metalloproteinases secreted by endothelial cells | [29] |
DC101 + doxorubicin | Leiomyosarcoma SKLMS-1 and RMS RD cell lines and xenografts | ↑ Antitumor and antiangiogenic effects ↓ MVD and neovascularization ↑ Apoptosis of endothelial cells ↓ Endothelial cell migration, proliferation, tube-like formation | [28] |
TNP-470 + etoposide | Angiosarcoma ISOS-1 cell line and xenograft | ↑ Antitumor effects ↑ Growth inhibition | [61] |